Liftstream is an executive search recruitment company in the life sciences sector
Massachusetts biotech continues to excite with new investments
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Abingworth Management, BioPharma America, Biotechnology cluster, Boston, Brookside Capital, Cristina Csimma, Cydan, David Mott, Deerfield, DELPHI, Dicer Substrate siRNA, Dicerna Pharmaceuticals, drug delivery technologies, Duchenne Muscular Dystrophy, EDI200, Edimer Pharmaceuticals, EnCore™, exon skipping, Exportin-1, Forsite Capital Management, Genzyme, Inhibitors of Nuclear Export, innovation, investors, Karyopharm Therapeutics, Massachusetts, Neil Kirby, New Enterprise Associates, New Leaf Venture Partners, NEZ, Omega Funds, oncology market, Orphan Drug, Prosensa, RA Capital, Rare Disease, Sanofi, Series B, SR One, Third Rock Ventures, TKT, undruggable disease, Vertex Pharmaceuticals, X-linked Hypohidrotic Ectodermal Dysplasia, XLHED
Leave a comment
Kurma Life Science Partners Launches new Biotech Fund for Rare Diseases
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Avalon Ventures, BLiNK, CDC Enterprise, DMD, Duchenne Muscular Dystrophy, European Research Institutes, France, GSK, Idinvest Partners, KLS Partners, Kurma, Kurma Biofund, Kurma Life Science Partners, NEA, New Enterprise Associates, oncology, Orphan drugs, partnering, Prosensa, rare diseases, VC, venture capital
Leave a comment
It’s as simple as ADC for Mersana Therapeutics
Authored by Karl Simpson
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged ADC, American Association for Cancer Researc, Antibody-drug conjugates, David Mott, Endo Pharmaceuticals, Fidelity Biosciences, Immunogen, Mersana Therapeutics, NEA, New Enterprise Associates, Pfizer Venture Fund, PureTech Ventures, Roche, seattle genetics, Timothy B. Lowinger, Washington
Leave a comment
13 Life Science Leaders to watch in 2013
Authored by Liftstream
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Abbott, AbbVie, Amgen, Angus Russell, AstraZeneca, Bluebird bio, Cancer Vaccine, CEO, Cystic Fibrosis, Dalvir Gill, David Mott, Director General EFPIA, EFPIA, EMEA, Erbitux, FDA, Flemming Ornskov, Foundation Medicine, FoundationOne, Gattex, Gene therapy, Gilead Sciences, Glybera, HCV, Hepatitis, Humira, INSPIRE, Jeff Leiden, Jeremy Levin, John Martin, Kalydeco, Karl-Ludwig Kley, Lotus Tissue Repair, Merck KGaA, Michael Pellini, Natpara, New Enterprise Associates, NP Pharmaceuticals, oncology, Orphan drugs, Pascal Soriot, rare diseases, Richard Bergstrom, Richard Gonzalez, Shire, Shire Speciality pharma, Sofosbuvir, Stimuvax, Takeda, Teva, TransCelerate, Ultragenyx, uniQure, Vertex Pharmaceuticals, Vyvanse
Leave a comment